Latest From Qiagen NV
November’s approvals include the US FDA approval of Medtronic’s In.Pact AV paclitaxel-coated balloon, for the treatment of arteriovenous access in patients with end-stage renal disease, and a CE mark that expands the indication for Edwards’ Sapien 3 TAVR device to include patients at low-risk during surgery.
Qiagen shares took a hit following a series of negative announcements, including lower than expected results for Q3 2019 and the departure of long-term CEO Peer Schatz. The company said it had been affected by poor sales growth in China.
The Swiss major has posted a strong set of financials for the second quarter and Vas Narasimhan is pleased with the roll-out of Zolgensma, Mayzent and Piqray.
Pacts In Medtech: Cook Will Sell Ambu’s Duodenoscopes; QXMedical Gets UMinnesota’s Bioresorbable Embolic
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in May and June 2019.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Qiagen NV
- Senior Management
Thierry Bernard, Interim CEO
Roland Sackers, CFO
Manuel O Mendez, SVP, Global Commercial Operations
Barthold Piening, PhD, SVP, Head of Global Operations
- Contact Info
Phone: (31) 77 3556600
Venlo, 5912 PL
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.